Noluthando Mwelase to Sarcoma, Kaposi
This is a "connection" page, showing publications Noluthando Mwelase has written about Sarcoma, Kaposi.
Connection Strength
0,918
-
Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067. J Acquir Immune Defic Syndr. 2024 Nov 01; 97(3):216-225.
Score: 0,227
-
Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings. J Acquir Immune Defic Syndr. 2023 10 01; 94(2):165-173.
Score: 0,211
-
Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy. J Acquir Immune Defic Syndr. 2020 08 01; 84(4):422-429.
Score: 0,169
-
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet. 2020 04 11; 395(10231):1195-1207.
Score: 0,164
-
As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis. 2018 07 02; 67(2):251-260.
Score: 0,146